Beam Therapeutics (BEAM) Prepaid Assets (2019 - 2026)
Beam Therapeutics (BEAM) posted quarterly Prepaid Assets of $55.3 million for Q1 2026, up 99.92% year-over-year from $27.7 million in Q1 2025, and up 135.54% quarter-over-quarter from $23.5 million in Q4 2025.
Analysis
Beam Therapeutics (BEAM) Prepaid Assets (2019 - 2026) Analysis & Trends
Beam Therapeutics (BEAM) has reported Prepaid Assets for 8 consecutive years, with $55.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Prepaid Assets rose 99.92% year-over-year to $55.3 million; the TTM figure through Mar 2026 stood at $55.3 million (up 99.92% YoY), while the FY2025 annual figure was $23.5 million, down 14.34% from the prior year.
- Prepaid Assets grew to $55.3 million in Q1 2026 per BEAM's latest filing, from $23.5 million in the prior quarter.
- Across five years, Prepaid Assets topped out at $55.3 million in Q1 2026 and bottomed at $13.8 million in Q2 2022.
- Historically, Prepaid Assets has averaged $23.6 million across 5 years, with a median of $23.5 million in 2025.
- Annual changes were most pronounced in 2022 — Prepaid Assets jumped 100.57% — and 2024, when it declined 17.88%.
- Beam Therapeutics' Prepaid Assets stood at $14.8 million in 2022, then jumped by 43.39% to $21.2 million in 2023, then grew by 29.49% to $27.4 million in 2024, then retreated by 14.34% to $23.5 million in 2025, then surged by 135.54% to $55.3 million in 2026.
- Business Quant data shows BEAM's Prepaid Assets at $55.3 million in Q1 2026, $23.5 million in Q4 2025, and $23.6 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Beam Therapeutics | 3.10 Bn | 3.10 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 25.67 Mn |
| Mar 31, 2026 | 55.30 Mn |
| Dec 31, 2025 | 23.48 Mn |
| Sep 30, 2025 | 23.58 Mn |
| Jun 30, 2025 | 25.13 Mn |
| Mar 31, 2025 | 27.66 Mn |
| Dec 31, 2024 | 27.41 Mn |
| Sep 30, 2024 | 19.78 Mn |
| Jun 30, 2024 | 21.28 Mn |
| Mar 31, 2024 | 27.16 Mn |
| Dec 31, 2023 | 21.17 Mn |
| Sep 30, 2023 | 24.08 Mn |
| Jun 30, 2023 | 21.79 Mn |
| Mar 31, 2023 | 23.56 Mn |
| Dec 31, 2022 | 14.76 Mn |
| Sep 30, 2022 | 14.36 Mn |
| Jun 30, 2022 | 13.78 Mn |
| Mar 31, 2022 | 16.88 Mn |
| Dec 31, 2021 | 7.36 Mn |
| Sep 30, 2021 | 8.02 Mn |